Placeholder

Preclinical Development: Linking the Lab to Human Trials

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1978. Category: .

Product Description

The challenge of pharmaceutical discovery and development as a whole is that a large number of conditions need to be met in order for a single molecular entity to successfully reach the market, says Thomas Jones, Ph.D., senior director, toxicology and pathology, Eli Lilly and Company.
“The molecule needs to have the appropriate specificity and potency against the intended targets, it needs the right biopharmaceutical and ADME characteristics to be absorbed and reach the site of action, it needs to be able to be manufactured, and of course it needs to be…

Sidebar:
Microdosing: A Compelling Advantage

Experts on this topic
Thomas Jones, Ph.D., Senior Director, Toxicology and Pathology, Eli Lilly and Company
Jean-Jacques Garaud, M.D., Global Head, Pharmaceutical Research and Early Development, Roche
Peter Smith, Ph.D., Senior VP, Nonclinical Development Sciences at Millennium Pharmaceuticals Inc.: The Takeda Oncology Company
Alain Stricker-Krongrad, Ph.D., Chief Scientific Officer at Charles River

FEEDBACK